top of page

Rafarma Pharmaceuticals, Inc. enters new distribution agreement with Amber Pharma Distribution Group

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group, a boutique international business development firm. The principals of Amber Pharma have more than 75 years of combined international business development experience in a wide range of industry sectors including pharmaceuticals, finance, software, telecommunications and trade. It is intended that this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24 to 36 months.

CEO Dave Anderson stated: "We are delighted to form this strategic alliance with Amber Pharma. This is just the beginning of Rafarma's aggressive expansion into producing high-quality pharmaceutical products with partners all over the globe. If any distributor, supplier or retail provider is looking for state-of-the-art pharma production at competitive pricing, the Terbuny plant is the place, and its production capacity is still expanding."


Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of the nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,", "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

SOURCE: Rafarma Pharmaceuticals, Inc.


bottom of page